A2A Pharmaceuticals, Inc., 10% Owner at Biomea Fusion, Inc. (BMEA), sold 200,000 shares at $29.12 ($5.8M) on 2023-04-20, disclosed to the SEC on 2023-04-26.
Open-market sale of $5.8M BMEA by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Negative factors outweigh the positive ones.
| Filing → |
| BMEA | SELL | 2023-05-10 | $8.6M | — | Filing → |
| BMEA | SELL | 2023-04-06 | $6.3M | — | Filing → |
| BMEA | BUY | 2022-08-19 | $426K | — | Filing → |